Green light for 'medicinal' cannabis trials
Your support helps us to tell the story
From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or producing our latest documentary, 'The A Word', which shines a light on the American women fighting for reproductive rights, we know how important it is to parse out the facts from the messaging.
At such a critical moment in US history, we need reporters on the ground. Your donation allows us to keep sending journalists to speak to both sides of the story.
The Independent is trusted by Americans across the entire political spectrum. And unlike many other quality news outlets, we choose not to lock Americans out of our reporting and analysis with paywalls. We believe quality journalism should be available to everyone, paid for by those who can afford it.
Your support makes all the difference.Britain's drug regulatory authority has given the go-ahead for the first full-scale patient trials of therapeutic cannabis products, it was disclosed today.
The Phase Two trials will involve patients suffering from multiple sclerosis, spinal cord injury, severe pain and spasticity.
GW Pharmaceuticals, which has a Home Office licence to use cannabis in medical research, was given permission for the trials by the Medicines Control Agency.
The company said the trials, taking place at a number of locations, would commence "in the near future" and recruit some 2,000 patients over the next two to three years.
The first trial will be led by Dr Willy Notcutt at the Pain Relief Clinic at the James Paget Hospital, Great Yarmouth.
Dr Notcutt said: "Our aim is to test some of the claims which have been made for the medicinal qualities of cannabis in a structured clinical research programme. This is an exciting moment, and we hope very much that our findings will lead to significant improvements in the pain relief available for sufferers of MS and other debilitating conditions."
Patients will take different formulations of compounds derived from cannabis using an under-the-tongue spray.
The aim of the programme is to develop cannabis-based prescription medicines which could be on sale as early as 2003.
Join our commenting forum
Join thought-provoking conversations, follow other Independent readers and see their replies
Comments